Skip to content
PreclinicalMitochondrialOralDailyPartial data

5-Amino-1MQ

Small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT) that increases intracellular NAD+ and SAM and may reduce adiposity.

◆ Editorial note

Small molecule NNMT inhibitor, not a peptide. Included for its metabolic and adipose effects.

§ 01   Overview

Overview

Small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT) that increases intracellular NAD+ and SAM and may reduce adiposity.

Strong mouse model data. No substantial human clinical trials published to date.

§ 02   Mechanism

Mechanism of action

5-Amino-1MQ inhibits NNMT, an enzyme overexpressed in white adipose tissue of obese subjects. Inhibition preserves methyl donors and NAD+, shifting adipocytes toward a leaner, more thermogenic phenotype in preclinical models.

  • 01Preclinical reduction in adiposity
  • 02Increased NAD+ and SAM availability
  • 03Improved metabolic markers in animal studies

§ 03   Dosing

Dosing protocol

Standard Protocol

Dose Range
50 – 150 mg daily (anecdotal)
Starting Dose
50 mg daily
Route
Oral
Timing
AM
Frequency
Daily
Cycle
8 weeks on, 4 off

§ 04   Evidence

Evidence & research

Preclinical

Strong mouse model data. No substantial human clinical trials published to date.

FDA Status

Not FDA-approved. Sold as research chemical.

§ 06   News

In the news

7 articles from the last 12 months · updates hourly

§ 07   Sourcing

Sourcing & supply

Regulatory status

Research-only, no commercial channel

No commercial channel exists. Available only as a research reagent from RUO suppliers. Use in humans is not established.

Research-use-only · 1

Research-use-only

Limitless Life Nootropics

'Only BBB-accredited peptide company' (since 2020). Claims three-lab third-party testing. Broad catalog.

BBB Accredited +1
Visit

Listings are informational, not endorsement. Verify credentials and flags against FDA and PCAB databases before purchasing. Full directory & how to verify →

§ 09   Safety

Safety & side effects

Side effects

  • 01Insufficient human safety data
  • 02Possible methylation effects

Contraindications

None specified.

§ 10   Questions

5-Amino-1MQ FAQ

What is 5-Amino-1MQ?
Small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT) that increases intracellular NAD+ and SAM and may reduce adiposity. 5-Amino-1MQ inhibits NNMT, an enzyme overexpressed in white adipose tissue of obese subjects. Inhibition preserves methyl donors and NAD+, shifting adipocytes toward a leaner, more thermogenic phenotype in preclinical models.
What is 5-Amino-1MQ used for?
Reported uses include preclinical reduction in adiposity, increased nad+ and sam availability, and improved metabolic markers in animal studies. Evidence strength is rated Preclinical — see the evidence section for detail.
How is 5-Amino-1MQ dosed?
Commonly referenced dosing is 50 – 150 mg daily (anecdotal), administered Oral. This is educational reference only; consult a licensed clinician before use.
What are the side effects of 5-Amino-1MQ?
Commonly reported side effects include insufficient human safety data and possible methylation effects. This list is not exhaustive.
Is 5-Amino-1MQ legal?
No commercial channel exists. Available only as a research reagent from RUO suppliers. Use in humans is not established. FDA status: Not FDA-approved. Sold as research chemical..

This site is for educational and research purposes only. It does not constitute medical advice. Always consult a qualified healthcare provider before using any peptide or supplement.